scholarly journals Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials

2017 ◽  
Vol 102 (2) ◽  
pp. 321-331 ◽  
Author(s):  
RM Savic ◽  
M Weiner ◽  
WR MacKenzie ◽  
M Engle ◽  
WC Whitworth ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pulmonary Tuberculosis ◽  
Phase Ii ◽  
Optimal Dose ◽  
Two Phase ◽  
Phase Ii Clinical Trials ◽  
Exposure Response

scholarly journals Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials

2020 ◽  
Vol 9 (11) ◽  
pp. 3656-3667
Author(s):  
Makoto Endo ◽  
Shunji Takahashi ◽  
Nobuhito Araki ◽  
Hideshi Sugiura ◽  
Takafumi Ueda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase Ii ◽  
Tumor Response ◽  
Time Lapse ◽  
Pooled Analysis ◽  
Two Phase ◽  
Phase Ii Clinical Trials

scholarly journals SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Matthias Kroiss ◽  
Maria-Elisabeth Goebeler ◽  
Camilo Jimenez ◽  
Uwe Malzahn ◽  
Martin Fassnacht ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Adrenocortical Carcinoma ◽  
Two Phase ◽  
Phase Ii Clinical Trials

Analysis of mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples from two phase II clinical trials using a Sequenom-based approach.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1548-1548
Author(s):  
Maria Orr ◽  
James Sherwood ◽  
Gael McWalter ◽  
Emma Donald
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Biomarker Discovery ◽  
Biological Significance ◽  
Two Phase ◽  
Phase Ii Clinical Trials ◽  
Formalin Fixed Paraffin ◽  
Ffpe Samples ◽  
Formalin Fixed Paraffin Embedded ◽  
Formalin Fixed

1548 Background: Analysis of tumour samples for biomarker discovery, personalised health care and disease stratification is becoming increasingly important. Methods to detect somatic mutations are often limited by the requirement for a significant amount of input DNA, low sensitivity or low sample throughput. The aim of this work was to obtain a comprehensive mutation profile of tumour samples taken from patients enrolled on two Phase II clinical trials. A Sequenom based approach was used to determine mutation profiles for the samples so that these could be correlated with response at some future date. Methods: After successfully piloting the Sequenom MassArray 4 platform on formalin fixed paraffin embedded (FFPE) tumour samples and tumour cell line admixes, we ran an exploratory analysis of 177 melanoma and 230 non small cell lung cancer (NSCLC) FFPE samples collected from two phase II clinical trials. DNA was extracted from the FFPE samples using the QIAmp DNA FFPE Tissue Kit (Qiagen). We designed a panel of 86 assays in 14 genes covering approximately 160+ mutations. Mutations were chosen based on mutation frequency and biological significance in these tumour types. Results: Using this approach we were able to detect concomitant mutation profiles in a significant percentage of samples using only approximately 20uL of FFPE DNA (500 copies/µL average). Mutation status concordance was over 97% in BRAF and KRAS when compared to data generated via other approaches (sequencing, ARMS). Conclusions: Using Sequenom to screen tumour material, collected during clinical trials, is a feasible, rapid and comprehensive approach. Such an approach can be used to identify mutation profiles which correlate with patient response, potentially identify further patient stratification and help generate new hypotheses for further exploration.

Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity

2020 ◽  
Vol 20 (19) ◽  
pp. 2019-2035
Author(s):  
Esmaeil Sheikh Ahmadi ◽  
Amir Tajbakhsh ◽  
Milad Iranshahy ◽  
Javad Asili ◽  
Nadine Kretschmer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Biological Activity ◽  
Small Molecules ◽  
Anticancer Activity ◽  
Clinical Significance ◽  
Phase Ii ◽  
Biological Activities ◽  
Phase Ii Clinical Trials ◽  
Naturally Occurring ◽  
The Subject

Naturally occurring naphthoquinones (NQs) comprising highly reactive small molecules are the subject of increasing attention due to their promising biological activities such as antioxidant, antimicrobial, apoptosis-inducing activities, and especially anticancer activity. Lapachol, lapachone, and napabucasin belong to the NQs and are in phase II clinical trials for the treatment of many cancers. This review aims to provide a comprehensive and updated overview on the biological activities of several new NQs isolated from different species of plants reported from January 2013 to January 2020, their potential therapeutic applications and their clinical significance.

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials

2009 ◽  
Vol 52 (4) ◽  
pp. 283-288 ◽  
Author(s):  
R. Barbouche ◽  
E. Fenouillet ◽  
M.-J. Papandréou ◽  
M.P. Kiény ◽  
J M. Sabatier
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Peptide Drug ◽  
Phase Ii Clinical Trials ◽  
Hiv Envelope
Sign in / Sign up

Export Citation Format

Share Document